Bioxytran: Eliminating viruses and prolonging lifespans by blocking the problematic Galectin glycoproteins

Potentially game changing Galectin therapeutics from the man who literally wrote the book on them.

Combating Viruses and Fighting Stroke

Unless you’re lucky, you probably know someone who’s been impacted by COVID, Influenza, RSV or Stroke. The numbers are staggering.

To give you an idea, in the U.S alone: over 1 million people have died from COVID, 20% of COVID infections have led to the dreaded long COVID, ~750K people were hospitalized with influenza in 2020 and Americans have a stroke every 40 seconds or die from one every 3.5 minutes.

Outside the human cost of these diseases, influenza costs the U.S over $10.4 billion annually, stroke related costs total $66 billion and extra medical costs related to Long COVID could top $528 billion.

Imagine a world where that wasn’t the reality.

Enter Bioxytran, a clinical stage pharma company looking to eliminate viruses and prolong lifespans through Galectin blockers.

Summary

👉 The Mind-blowing Amount We Spend Treating Viruses and Strokes

👉 Bringing Galectins to the Forefront…huh?

👉 Betting on the Guy Who Literally Wrote the Book

👉 The Bottom Line

The Mind-blowing Amount We Spend Treating Viruses and Strokes

You’re probably not surprised that the anti-viral drug market is staggeringly large and continues to grow. In 2021, spending on antivirals totaled $48 billion globally and is set to climb to $64B by 2028. Of that amount, Coronavirus related antivirals took a 17% market share.

Similarly, spending on stroke management is set to total $37 billion in 2022 and reach $59.5 billion by 2032.

Despite all the money being pumped into these treatments, its possible current drug makers have been missing a critical piece of the puzzle to unlocking better and more effective treatments – Galectins.

A unique protein found in many of the body’s tissues and organs, Galectins have been shown to play a key role in our immune systems, and the regulation of cell growth and death.

Abnormal activity related to Galectins conversely, may be involved in types of cancers (breast, colon, lung), autoimmune diseases, cardiovascular disease, and neurogenerative conditions like Alzheimer’s.

There are mountains of evidence to suggest that Galectins are linked to these chronic diseases, but there are few drugs out there that explicitly target or inhibit them. Galectin science is comparatively underdeveloped, but Bioxytran is looking to change that by pioneering Glycovirology.

Talk about getting in on the ground floor!

Bringing Galectins to the Forefront.. huh?

Given the generational opportunity to help relieve the pain caused by viruses and degenerative diseases, Bioxytran is harnessing the power of Galectin science to eliminate viruses and prolong lifespans.

The company’s leading management team, headed up by the guy who literally wrote the book on Galectins (Dr. David Platt), is in the process of trying to complete clinical trials to approve its first oral Galectin therapeutic (ProLectin-M) focused on COVID 19.

Initial results for the treatment have been extremely promising. Those who ingested the therapeutic experienced drastically reduced infectivity levels and were PCR negative 88% of the time after only 3 days and fully cured after a week. Instead of focusing on antibodies like other COVID therapeutics, ProLectin-M attracts the virus, binds to it and gets rid of it. The results speak for themselves!

Similar Covid therapeutics have generated over $30 billion in global sales so ProLectin- M could become a big hit.

Source: Bioxytran Investor Presentation

Should ProLectin-M get approval, additional Galectin inhibitor treatments focused on Long COVID, Conjunctivitis, Influenza and RSV are set to come down the pipe in 2023.

When not creating solutions for potentially ending viruses, Bioxytran is also in pre-clinical stages for the evaluation of it’s revolutionary Oxygen Bridge (a chemical bond that helps the body transport Oxygen through the bloodstream) called BXT-25. 5,000 times smaller than a red blood cell, BXT-25 may be able to penetrate blood clots faster than anything on the market, making sure the body can transport oxygen with greater volume and efficiency.

For someone experiencing a stroke, something like this near by could mean life or death.

BXT-25 is a longer term play for Bioxytran given it’s immediate focus on ProLectin-M, but the company’s proprietary technology and advanced discoveries already made in this area, make this side of its commercialization pipeline something important to watch.

That’s what we call a strong 1-2 punch.

Betting on the Guy Who Literally Wrote the Book

Bioxytran’s experienced management team and proprietary technology makes it a company worth following as it heads for drug approval, commercialization and pre-clinicals with BXT-25.

In fact, one of the main reasons why widespread interest in this area hasn’t caught fire despite 4000 journal articles been published about Galectins, is due to lack of talent and expertise in the space. Big Pharma’s got nothing on Dr. David Platt.

With ProLectin-M and 5 patents in hand (1 provisional), Bioxytran plans to licence its technology and partner with large pharmaceutical companies to scale production and distribution.

By going after Covid related applications, the company is optimistic to fast-track approvals and insulate its sales pipeline if big pharma doesn’t play nice. Covid focused therapeutics can be sold directly to governments from their producers and don’t need big pharma for distribution.

The company’s strategy of getting the drug to market as quick as humanly possible clearly reflects Dr. Platt’s extensive experience founding four publicly traded companies, raising $150m in the public markets and creating $1B in shareholder value.

The Bottom Line

With the company already making major progress in its clinical developments for it’s primarily Galectin platform, establishing new operating subsidiaries around the world, and setting the stage of the build out of it’s oxygen transport molecules, it’s hard not to be excited about Bioxytran’s potential.

Near term catalysts include the approval of ProLectin-M, progression of clinical trials across the ProLectin portfolio, the establishment of big pharma partnerships or preclinical progression of BXT-25.

Check out their website to learn more.

Gritcapital.substack.com (“Grit”) is a website owned and operated by Substack. Grit is paid fees by the companies that make investment offerings on this website. Be aware that payment of these fees may put Grit in a conflict of interest with the investor. By accessing this website or any page thereof, you agree to be bound by the Terms of Use and Privacy Policy, in effect at the time you access this website or any page thereof. The Terms of Use and Privacy Policy may be amended from time to time. Nothing on this website shall constitute an offer to sell, or a solicitation of an offer to buy or subscribe for, any securities to any person in any jurisdiction where such an offer or solicitation is against the law or to anyone to whom it is unlawful to make such offer or solicitation. Grit is not an underwriter, broker-dealer, Title III crowdfunding portal or a valuation service and does not engage in any activities requiring any such registration. Grit does not provide advice on investments or structure transactions. Offerings made under Regulation A under the U.S. Securities Act of 1933, as amended (the “Securities Act”) are available to U.S. investors who are “accredited investors” as defined by Rule 501 of Regulation D under the Securities Act well as non-accredited investors, who are subject to certain investment limitations as set forth in Regulation A under the Securities Act. In order to invest in Regulation A offerings, investors may be asked to fill out a certification and provide necessary documentation as proof of your income and/or net worth to verify that you are qualified to invest in offerings posted on this website. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. Grit does not verify the adequacy, accuracy or completeness of any information. Neither Grit nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, valuations of securities or completeness of any information on this site or the use of information on this site. Neither Grit nor any of its directors, officers, employees, representatives, affiliates or agents shall have any liability whatsoever arising from any error or incompleteness of fact, or lack of care in the preparation of, any of the materials posted on this website. Investing in securities, especially those issued by start-up companies, involves substantial risk. investors should be able to bear the loss of their entire investment and should make their own determination of whether or not to make any investment based on their own independent evaluation and analysis.

The information contained on this website has been prepared by the paid advertiser BioXyTran Inc. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser. BioXyTran Inc. has paid $75,000 to have this content (in addition to other content on other social media sites) created and published. GetVersed is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.

The information contained on this website has been prepared by the paid advertiser. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser.

Grit Capital Corporation is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.

THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN. INVESTORS SHOULD OBTAIN INDIVIDUAL FINANCIAL ADVICE BASED ON THEIR OWN CIRCUMSTANCES BEFORE MAKING AN INVESTMENT DECISION.

No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.

Any projections, market outlooks or estimates herein are forward looking statements and are inherently unreliable. They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur. Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein. The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and the publisher undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.

The publisher, its affiliates, and clients of the publisher or its affiliates may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.

Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.